A message from Altum Sequencing

Altum Sequencing is pitching a €5M raise to scale its AI-enabled liquid biopsy and ultra-sensitive NGS platform for cancer monitoring, with applications across pharma, hospitals, and clinical research. For CIOs and technology leaders, the strategic signal is the growing convergence of diagnostics, AI analytics, and longitudinal patient data into a scalable clinical platform that could improve earlier relapse detection, resistance monitoring, and treatment decisions while creating new integration, data governance, and workflow demands for IT organizations.